Recently published report Global Multiple Sclerosis Drug Market 2010-2025

PRLog (Press Release) - Mar 15, 2010 -
Revenues for MS treatments will rise significantly from 2010 to 2025, our new study reveals. Rising disease prevalence, expanding patient populations, technological advances and widening healthcare provision for MS will drive the market upwards. In Global Multiple Sclerosis Drug Market 2010-2025 we analyse and explain trends in this market, providing sales forecasts and other core analyses that you require. Our report explains why the market will expand, revealing where the most-exciting developments will lie.

Which multiple sclerosis products will lead the market from 2010 onwards? Where will the best commercial opportunities lie in future years? What are the most-promising R&D pipeline developments? What are the most-crucial drivers and restraints for the treatment of MS? This report will help you to understand current trends and future opportunities in this industry and market. In particular, our new report covers leading products in depth, focussing on both commercial and therapeutic prospects from 2010 to 2025:
• Copaxone
• Avonex
• Rebif
• Betaferon
• Tysabri.

Comprehensive analysis of the global multiple sclerosis drug market

Global Multiple Sclerosis Drug Market 2010-2025 critically examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 45 tables and figures included, as well as three original interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses to benefit your work.

Why you should buy Global Multiple Sclerosis Drug Market 2010-2025

Our report will provide you with the following benefits in particular:
• You will assess the current market for multiple sclerosis drugs, with informed discussions
• You will analyse the future MS drugs market, including a global sales forecast from 2010 to 2025, with informed discussions
• You will receive sales forecasts for the leading MS drugs from 2010 to 2025, with detailed supporting information
• You will receive sales forecasts for leading national markets from 2010 to 2025 (US, Japan, Germany, France, UK, Italy, Spain, India and China), with geographical market characteristics discussed
• You will examine the leading companies in this market and their future outlook
• You will examine commercial drivers and restraints in depth
• You will discover the most-exciting R&D developments in this sector
• You will read expert opinions from our original survey, with full interview transcripts provided.

You can obtain this report today

Nobody with an interest in the multiple sclerosis treatments market should overlook our new study. We predict that there will be dynamic changes within this market area from 2010 onwards. The scope for therapeutic and commercial advances in MS treatment is great. Our report provides essential information to help you take advantage of the MS therapeutics market. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Contact person:

Bijal Patel
bijal.patel@visiongainglobal.com
Phone: 0044 (0)20 75499946

Visiongain Ltd.
4th Floor, BSG House
226-236 City Road
London
EC1V 2QY
United Kigdom